Lonza Completes Transformation to Pure-Play CDMO: Key Details for Investors
Lonza Completes Transformation to Pure-Play CDMO: Key Details for Investors
Overview
Lonza Group Ltd has announced the successful completion of its transformation into a pure-play Contract Development and Manufacturing Organization (CDMO) following the divestment of its Capsules & Health Ingredients (CHI) business. This marks the completion of a major corporate restructuring involving four divestments within less than two years, positioning Lonza to focus exclusively on its fast-growing CDMO operations.
Key Points from the Announcement
-
Divestment of CHI: Lonza reached an agreement to sell its CHI business to Lone Star Funds, a private equity sponsor, for an enterprise value of CHF 2.3 billion (USD 3 billion). Importantly, mechanisms are in place to potentially deliver total proceeds at or above CHF 3 billion (~USD 4 billion) for Lonza upon full exit.
-
Immediate and Future Proceeds: Lonza will receive CHF 1.7 billion in upfront cash and will retain a 40% stake in the CHI business, allowing for preferential participation in future value creation upon a full exit. The company expects total proceeds to reach or exceed CHF 3 billion, depending on future performance and exit conditions.
-
Accounting Impact: The retained 40% stake will be accounted for as an investment in an associated company. Lonza will book a non-cash impairment estimated at CHF 1.3 billion in FY 2025, with no impact on CDMO financials.
-
Strategic Use of Proceeds: Proceeds from the sale will be allocated according to Lonza’s disciplined capital allocation framework. This includes planned bolt-on M&A activity and a CHF 500 million share buyback, reinforcing the company’s commitment to returning value to shareholders while fueling future growth.
-
Pure-Play CDMO Focus: With the CHI divestment, Lonza will now operate exclusively across three integrated CDMO business platforms: Specialized Modalities, Integrated Biologics, and Advanced Synthesis. The company’s technology platforms cover the most attractive and fast-growing segments of the pharma market, with over 90% of the addressable CDMO market accessible to Lonza.
-
Market Position and Growth Outlook: Lonza’s addressable CDMO market is estimated at ~\$100 billion with an expected CAGR of 8–10% (2025–2030). The company’s CDMO business is expected to achieve organic sales growth of low teens percent, and CORE EBITDA growth ahead of sales, with a projected EBITDA margin above 32% in 2026.
-
Investment Plans: Lonza plans to invest more than CHF 7 billion until 2030 (excluding M&A), focusing on capacity expansion, technology advancement, and opportunistic inorganic growth.
-
Recent M&A Activity: The company highlights recent deals including the acquisition of Redberry microbiology testing solutions, the Vacaville (US) biologics site, and Synaffix ADC technology platform.
-
Commitment to Shareholders: Lonza will maintain or increase its dividend per share each year and execute a CHF 500 million share buyback after the CHI divestment closes.
-
Financial Discipline: The company reaffirms its commitment to a BBB+ credit rating and disciplined capital allocation, ensuring growth investments are secured by a strong pipeline or anchor customers and diversified across technologies.
Shareholder-Relevant and Potentially Price Sensitive Information
-
The CHI divestment immediately strengthens Lonza’s balance sheet and unlocks capital for growth and shareholder returns.
-
The CHF 500 million share buyback and the potential for total proceeds at or above CHF 3 billion represent direct value creation for shareholders.
-
The non-cash impairment of CHF 1.3 billion in FY 2025 is a significant accounting adjustment but will not affect the underlying financials of the continuing CDMO business.
-
The strategic shift to a pure-play CDMO with a focus on high-growth, high-margin market segments could further enhance Lonza’s long-term valuation and investor appeal.
-
Ongoing and future M&A activity, plus planned investments (>CHF 7 billion by 2030), suggest a strong commitment to scaling operations and innovation, which may impact future earnings and share price performance.
Looking Ahead
Lonza is now fully focused on its role as a leading, integrated CDMO, leveraging its advanced technology platforms across the pharma value chain. The company’s clear capital allocation framework, strategic investments, and consistent shareholder returns position it for continued profitable growth.
Investors should monitor upcoming events such as the Q1 2026 Qualitative Update and Half-Year Results, as well as the execution of the share buyback and the progress of bolt-on M&A, which may provide further insights into the company’s growth trajectory and capital deployment.
Upcoming Investor Events
- 24 March 2026: BNP, London (UK)
- 25 March 2026: ZKB, Edinburgh (UK)
- 1 April 2026: Publication of Annual and Sustainability Reports
- 8 May 2026: Q1 2026 Qualitative Update & Annual General Meeting
- 15 May 2026: Dividend-Payment Date
- 22 July 2026: Half-Year Results 2026
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those projected. Investors are advised to refer to official Lonza communications and consult professional advisors before making investment decisions.
View Lonza Historical chart here
